Alpa Labs' board approved the financial results for the quarter ended June 30, 2026. Consolidated revenue came in at ₹23.93 Cr, with a profit of ₹0.98 Cr. The notice for the 38th Annual General Meeting was also approved.
Alpa Labs plans to explore a new overseas pharma & healthcare venture, 'Alpa Biopharm Limited,' in Nigeria with Blueseal Pharmaceuticals. This is an initial approval; no investment made yet.
Alpa Laboratories has revised its financial results filing for Q4 FY26 (ended March 31). This update clarifies or modifies previously shared financial figures.
Alpa Laboratories Limited has informed the Exchange regarding Cessation of Ms.Jyoti Jain as Non- Executive Independent Director of the company w.e.f. July 21, 2026.
